83.450USD+83.450æéå€ååŒÂ  (ET)
32.20BæäŸ¡ç·é¡
34.89çŽè¿12ã¶æPER
äž»èŠããŒã¿
80.000å§å€
84.700é«å€
11.93Måºæ¥é«
34.89çŽè¿12ã¶æPER
27.17äºæ³PER
--çŽè¿12ã¶æé
åœ
3.09%売買å転ç
74.540忥çµå€
79.665å®å€
701.96M売買代é
55.89æ ªäŸ¡åçç
10.89PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
13.90%ç·è³ç£å©çç
89.98052é±é«å€
2.50åºæ¥é«æ¯ç%
576.20MçŽå©ç
385.90Mæ ªåŒæ°
2.39181æ ªåœããå©çïŒEPSïŒ
1.44ããŒã¿å€
35.62%èªå·±è³æ¬å©çç
54.11052é±å®å€
6.75%æ¯ãå¹
63.44%ç²å©çç
32.20BæäŸ¡ç·é¡
2.08ãªã¹ã¯ãªã¿ãŒã³
2.22%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-30 äž»èŠã€ã³ãµã€ã
Dexcom Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»çæ©åš & å忥çã§ã®é äœã¯199äž15äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯86.50ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Dexcom Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Dexcom Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Dexcom Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Zimmer Biomet Holdings Inc
ZBH
31
Medline Ord Shs Class A
MDLN
29
ææšî
ææš
売ã(2)
äžç«(4)
è²·ã(1)
ç§»åå¹³å
売ã(0)
äžç«(0)
è²·ã(6)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Dexcom Incã®äŒæ¥æ
å ±î
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patientâs compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
äŒæ¥ã³ãŒãDXCM
äŒæ¥åDexcom Inc
æé«çµå¶è²¬ä»»è
ãCEOãMr. Jacob Steven (Jake) Leach
ãŠã§ããµã€ãhttps://www.dexcom.com/
æ ªäž»çµ±èšî
ãããã質å
Dexcom IncïŒDXCMïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îDexcom IncïŒDXCMïŒã®çŸåšã®æ ªäŸ¡ã¯74.57ã§ãã
Dexcom Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îDexcom Incã®ãã£ãã«ãŒã·ã³ãã«ã¯DXCMã§ãã
Dexcom Incã®52é±é«å€ã¯ãããã§ããïŒ
îDexcom Incã®52é±é«å€ã¯89.98ã§ãã
Dexcom Incã®52é±å®å€ã¯ãããã§ããïŒ
îDexcom Incã®52é±å®å€ã¯54.11ã§ãã
Dexcom Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îDexcom Incã®æäŸ¡ç·é¡ã¯28.78Bã§ãã
Dexcom Inc (DXCM) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãDexcom IncïŒDXCMïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯86.50ã§ãã
Dexcom Inc (DXCM) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îDexcom IncïŒDXCMïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯2.14ã§ãã